Completed PHASE2 INTERVENTIONAL 3-arm NCT00958100

Raltegravir Switch for Toxicity or Adverse Events (RaSTA)

Phase IIb Pilot Study for the Evaluation of the Safety and the Feasibility of Treatment Simplification to Tenofovir+Emtricitabine+Raltegravir or to Lamivudine+Abacavir+Raltegravir in Patients With Optimal Virological Control and Toxicity to the Current Combined Antiretroviral Regimen

Sponsor: Catholic University of the Sacred Heart

Conditions Antiretroviral Therapy HIV Infections HIV/AIDS

Interventions Abacavir free Lamivudine Abacavir Raltegravir tenofovir emtricitabine raltegravir

Updated 5 times since 2017 Last updated: Feb 3, 2015 Started: Aug 31, 2009 Primary completion: Nov 30, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00958100, this PHASE2 trial focuses on Antiretroviral Therapy and HIV Infections and remains completed. Sponsored by Catholic University of the Sacred Heart, it has been updated 5 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Catholic University of the Sacred Heart

Data source: Catholic University of the Sacred Heart

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rome, Italy